Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases

NCT03754140 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT03754140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03754140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Lead sponsor
Melanoma Institute Australia
Phase
Phase 2
Overall status
Withdrawn
Start date
May 20, 2020
Completion date
December 31, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

in-transit metastasis of cutaneous melanoma, melanoma